Findings showed nivolumab/relatlimab did not significantly improve recurrence-free survival compared with nivolumab monotherapy. A phase 3 trial evaluating nivolumab and relatlimab-rmbw (Opdualag ...

In a phase 3 trial known as NADINA, researchers randomly assigned patients with resectable, macroscopic stage III melanoma to two cycles of neoadjuvant ipilimumab plus nivolumab followed by ...

In the post hoc analysis, the benefit of adjuvant nivolumab was seen both in patients with MIBC who had previously received neoadjuvant chemotherapy and those who had not, and in patients with ...

Opens in a new tab or window SAN FRANCISCO -- Post-surgical adjuvant nivolumab (Opdivo) improved survival outcomes in muscle-invasive bladder cancer (MIBC), regardless of the use of neoadjuvant ...